Pacira BioSciences, Inc. PCRX Total Equity
Total Equity at other companies
Other financials
Where this comes from
Reported directly by Pacira BioSciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:StockholdersEquity.
The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacira BioSciences, Inc.'s total equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacira BioSciences, Inc.'s total equity?
- Pacira BioSciences, Inc. (PCRX) reported total equity of $653.89M in Q1 2026.
- How has Pacira BioSciences, Inc.'s total equity changed year-over-year?
- Pacira BioSciences, Inc.'s total equity decreased by 18.1% year-over-year, from $798.54M to $653.89M.
- What is the long-term trend for Pacira BioSciences, Inc.'s total equity?
- Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s total equity has grown at a 2.3% compound annual growth rate (CAGR), from $619.69M to $693.11M.
- What does total equity mean?
- Net assets attributable to shareholders — total assets minus total liabilities. Represents the book value of shareholders' ownership claim.